February 10, 2020 11:07 AM ESTUpdated February 12, 10:06 AM
R&D

Vivek Ra­maswamy's Ar­bu­tus kills an­oth­er pro­gram over safe­ty, stock takes an­oth­er hit

Jason Mast

Editor

Vivek Ra­maswamy and Roivant’s $100 mil­lion bet on Ar­bu­tus and their he­pati­tis B pipeline have seen bet­ter days.

Ra­maswamy made the bet in 2017 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times